|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.81 HKD | +2.06% |
|
+6.90% | -8.38% |
| 18/06 | Sinopharm Group Co. Ltd. Approves Ordinary Final Dividend for the Year Ended 31 December 2025, Payable on 18 August 2026 | CI |
| 27/04 | Earnings Season, Tehran Proposal Lift Asian Stock Markets | MT |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 4.06 | 4.06 | 3.73 | 2.87 | 2.75 | |||||
Return on Total Capital | 8.03 | 8.18 | 7.46 | 5.61 | 5.28 | |||||
Return On Equity % | 13.78 | 13.68 | 13.03 | 8.44 | 8.31 | |||||
Return on Common Equity | 13.12 | 13.12 | 12.69 | 9.19 | 8.79 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 8.45 | 8.59 | 8.13 | 7.57 | 7.25 | |||||
SG&A Margin | 4.45 | 4.51 | 4.39 | 4.38 | 4.18 | |||||
EBITDA Margin % | 4.39 | 4.49 | 4.09 | 3.42 | 3.35 | |||||
EBITA Margin % | 4.07 | 4.16 | 3.78 | 3.09 | 3.04 | |||||
EBIT Margin % | 4.03 | 4.12 | 3.74 | 3.05 | 3 | |||||
Income From Continuing Operations Margin % | 2.51 | 2.6 | 2.52 | 1.78 | 1.88 | |||||
Net Income Margin % | 1.49 | 1.54 | 1.52 | 1.21 | 1.24 | |||||
Net Avail. For Common Margin % | 1.49 | 1.54 | 1.52 | 1.21 | 1.24 | |||||
Normalized Net Income Margin | 1.21 | 1.26 | 1.2 | 1.19 | 1.13 | |||||
Levered Free Cash Flow Margin | -0.45 | 2.75 | 1.7 | -1.18 | 0.48 | |||||
Unlevered Free Cash Flow Margin | -0 | 3.15 | 2.01 | -0.89 | 0.73 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 1.61 | 1.58 | 1.59 | 1.51 | 1.47 | |||||
Fixed Assets Turnover | 27.21 | 28.28 | 30.17 | 29.57 | 30.38 | |||||
Receivables Turnover (Average Receivables) | 3.27 | 3.21 | 3.34 | 3.02 | 2.82 | |||||
Inventory Turnover (Average Inventory) | 9.68 | 8.98 | 9.06 | 8.83 | 8.49 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.33 | 1.36 | 1.39 | 1.39 | 1.41 | |||||
Quick Ratio | 1.02 | 1 | 1.06 | 1.06 | 1.07 | |||||
Operating Cash Flow to Current Liabilities | 0.04 | 0.09 | 0.07 | 0.05 | 0.06 | |||||
Days Sales Outstanding (Average Receivables) | 111.6 | 113.63 | 109.21 | 121.25 | 129.5 | |||||
Days Outstanding Inventory (Average Inventory) | 37.72 | 40.65 | 40.28 | 41.45 | 43 | |||||
Average Days Payable Outstanding | 91.38 | 94.25 | 94.63 | 100.42 | 102.9 | |||||
Cash Conversion Cycle (Average Days) | 57.93 | 60.03 | 54.86 | 62.28 | 69.6 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 68.61 | 63.22 | 61.32 | 60.3 | 52.89 | |||||
Total Debt / Total Capital | 40.69 | 38.73 | 38.01 | 37.62 | 34.59 | |||||
LT Debt/Equity | 11.71 | 13.59 | 14.34 | 9.39 | 4.58 | |||||
Long-Term Debt / Total Capital | 6.94 | 8.33 | 8.89 | 5.86 | 2.99 | |||||
Total Liabilities / Total Assets | 70.29 | 69.83 | 68.62 | 67.75 | 65.63 | |||||
EBIT / Interest Expense | 5.6 | 6.49 | 7.58 | 6.54 | 7.51 | |||||
EBITDA / Interest Expense | 6.61 | 7.63 | 9.02 | 8.2 | 9.29 | |||||
(EBITDA - Capex) / Interest Expense | 6.06 | 7.02 | 8.35 | 7.66 | 8.63 | |||||
Total Debt / EBITDA | 2.76 | 2.6 | 2.78 | 3.42 | 3.33 | |||||
Net Debt / EBITDA | 0.89 | 0.42 | 0.25 | 0.85 | 0.91 | |||||
Total Debt / (EBITDA - Capex) | 3.01 | 2.82 | 3 | 3.66 | 3.58 | |||||
Net Debt / (EBITDA - Capex) | 0.97 | 0.45 | 0.27 | 0.91 | 0.98 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 14.16 | 5.97 | 8.05 | -2.02 | -1.6 | |||||
Gross Profit, 1 Yr. Growth % | 9.24 | 7.68 | 2.27 | -8.77 | -5.84 | |||||
EBITDA, 1 Yr. Growth % | 9.64 | 8.22 | -1.51 | -18.17 | -3.54 | |||||
EBITA, 1 Yr. Growth % | 9.61 | 8.32 | -1.93 | -19.92 | -3.3 | |||||
EBIT, 1 Yr. Growth % | 9.85 | 8.48 | -1.96 | -20.16 | -3.31 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 8 | 9.8 | 4.63 | -30.55 | 3.94 | |||||
Net Income, 1 Yr. Growth % | 7.95 | 9.89 | 6.19 | -22.14 | 1.5 | |||||
Normalized Net Income, 1 Yr. Growth % | 10.54 | 10.34 | 3 | -2.29 | -7.09 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 7.63 | 9.81 | 6.19 | -22.1 | 1.37 | |||||
Accounts Receivable, 1 Yr. Growth % | 18.16 | -0.79 | 8.52 | 8.44 | 2.57 | |||||
Inventory, 1 Yr. Growth % | 9.37 | 18.3 | -1.47 | 3.87 | 1.59 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 2.71 | 1.23 | 1.27 | -1.33 | -7.15 | |||||
Total Assets, 1 Yr. Growth % | 7.77 | 8.75 | 5.1 | 2.46 | -0.63 | |||||
Tangible Book Value, 1 Yr. Growth % | 12.82 | 12.41 | 11.37 | 8.66 | 8.21 | |||||
Common Equity, 1 Yr. Growth % | 9.81 | 9.99 | 9.57 | 5.77 | 6.43 | |||||
Cash From Operations, 1 Yr. Growth % | -16.55 | 125.22 | -18.08 | -32.77 | 22.45 | |||||
Capital Expenditures, 1 Yr. Growth % | 9.3 | 2.57 | -7.88 | -24.91 | 1.65 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 24.59 | -743.47 | -33.06 | -168.09 | -140.12 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -107.29 | -99.26T | -30.91 | -143.45 | -180.72 | |||||
Dividend Per Share, 1 Yr. Growth % | 8.7 | 9.33 | 6.1 | -21.84 | 1.47 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 10.69 | 9.99 | 7 | 2.89 | -1.81 | |||||
Gross Profit, 2 Yr. CAGR % | 8.34 | 8.46 | 4.94 | -3.41 | -7.32 | |||||
EBITDA, 2 Yr. CAGR % | 7.28 | 8.93 | 3.24 | -10.22 | -11.15 | |||||
EBITA, 2 Yr. CAGR % | 7.01 | 8.96 | 3.07 | -11.38 | -12 | |||||
EBIT, 2 Yr. CAGR % | 7.45 | 9.17 | 3.13 | -11.53 | -12.14 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 10.91 | 8.9 | 7.19 | -14.76 | -15.04 | |||||
Net Income, 2 Yr. CAGR % | 11.39 | 8.91 | 8.02 | -9.07 | -11.1 | |||||
Normalized Net Income, 2 Yr. CAGR % | 7.1 | 10.41 | 6.61 | 0.32 | -4.72 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 8.81 | 8.71 | 8.09 | -9.12 | -11.14 | |||||
Accounts Receivable, 2 Yr. CAGR % | 18.63 | 8.27 | 3.76 | 8.48 | 5.46 | |||||
Inventory, 2 Yr. CAGR % | 9.96 | 13.75 | 7.96 | 1.16 | 2.72 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 3.66 | 1.97 | 1.25 | -0.04 | -4.29 | |||||
Total Assets, 2 Yr. CAGR % | 11.48 | 8.26 | 6.91 | 3.77 | 0.9 | |||||
Tangible Book Value, 2 Yr. CAGR % | 15.74 | 12.62 | 11.89 | 10.01 | 8.44 | |||||
Common Equity, 2 Yr. CAGR % | 14.24 | 9.9 | 9.78 | 7.65 | 6.1 | |||||
Cash From Operations, 2 Yr. CAGR % | -29.59 | 37.09 | 35.83 | -25.79 | -9.27 | |||||
Capital Expenditures, 2 Yr. CAGR % | -3.03 | 5.88 | -2.8 | -16.83 | -12.63 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -48.14 | 183.15 | 107.55 | -32.49 | -47.73 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -95.99 | 750.09 | 2.52T | -45.21 | -40.78 | |||||
Dividend Per Share, 2 Yr. CAGR % | 11.8 | 9.01 | 7.7 | -8.94 | -10.94 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 14.79 | 9.09 | 9.34 | 3.9 | 1.37 | |||||
Gross Profit, 3 Yr. CAGR % | 12.15 | 8.12 | 6.36 | 0.15 | -4.23 | |||||
EBITDA, 3 Yr. CAGR % | 11.13 | 7.59 | 5.33 | -4.45 | -8.05 | |||||
EBITA, 3 Yr. CAGR % | 10.83 | 7.44 | 5.2 | -5.25 | -8.76 | |||||
EBIT, 3 Yr. CAGR % | 10.85 | 7.79 | 5.32 | -5.3 | -8.87 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 11.58 | 10.54 | 7.46 | -7.25 | -8.93 | |||||
Net Income, 3 Yr. CAGR % | 9.96 | 10.89 | 8 | -3.14 | -5.67 | |||||
Normalized Net Income, 3 Yr. CAGR % | 9.46 | 8.15 | 7.88 | 3.55 | -2.21 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 8.25 | 9.14 | 7.94 | -3.14 | -5.75 | |||||
Accounts Receivable, 3 Yr. CAGR % | 17.39 | 11.77 | 8.35 | 5.3 | 6.47 | |||||
Inventory, 3 Yr. CAGR % | 13.32 | 12.67 | 8.43 | 6.58 | 1.3 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 20.74 | 2.84 | 1.74 | 0.38 | -2.47 | |||||
Total Assets, 3 Yr. CAGR % | 12.47 | 10.56 | 7.2 | 5.41 | 2.29 | |||||
Tangible Book Value, 3 Yr. CAGR % | 13.37 | 14.62 | 12.2 | 10.8 | 9.41 | |||||
Common Equity, 3 Yr. CAGR % | 13.06 | 12.8 | 9.79 | 8.43 | 7.24 | |||||
Cash From Operations, 3 Yr. CAGR % | 36.58 | 3.74 | 15.47 | 7.45 | -12.3 | |||||
Capital Expenditures, 3 Yr. CAGR % | -13.82 | -1.2 | 1.08 | -10.81 | -11.08 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -40.14 | 20.06 | 75.08 | 43.14 | -43.24 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -87.55 | 16.76 | 268.23 | 567.7 | -37.66 | |||||
Dividend Per Share, 3 Yr. CAGR % | 8.33 | 10.97 | 8.03 | -3.21 | -5.59 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 15.06 | 12.36 | 11.61 | 6.57 | 4.73 | |||||
Gross Profit, 5 Yr. CAGR % | 16.34 | 12.74 | 9.21 | 3.35 | 0.66 | |||||
EBITDA, 5 Yr. CAGR % | 15.45 | 11.67 | 7.91 | 0.08 | -1.6 | |||||
EBITA, 5 Yr. CAGR % | 15.36 | 11.56 | 7.66 | -0.52 | -2.05 | |||||
EBIT, 5 Yr. CAGR % | 15.52 | 11.64 | 7.69 | -0.4 | -2.04 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 13.65 | 10.61 | 9.8 | -0.37 | -2.18 | |||||
Net Income, 5 Yr. CAGR % | 10.79 | 8.86 | 9.18 | 2.43 | -0.09 | |||||
Normalized Net Income, 5 Yr. CAGR % | 14.23 | 13.46 | 8.29 | 4.95 | 2.65 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 8.16 | 7.76 | 8.19 | 1.47 | -0.17 | |||||
Accounts Receivable, 5 Yr. CAGR % | 19.53 | 16.06 | 11.73 | 10.44 | 7.19 | |||||
Inventory, 5 Yr. CAGR % | 14.86 | 15.01 | 11.15 | 7.92 | 6.11 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 23.51 | 16.88 | 12.53 | 1.68 | -0.72 | |||||
Total Assets, 5 Yr. CAGR % | 16.29 | 13.85 | 10.21 | 7.8 | 4.63 | |||||
Tangible Book Value, 5 Yr. CAGR % | 15.07 | 13.27 | 12.77 | 12.75 | 10.68 | |||||
Common Equity, 5 Yr. CAGR % | 14.24 | 12.19 | 11.74 | 10.71 | 8.3 | |||||
Cash From Operations, 5 Yr. CAGR % | 0.11 | 45.56 | 36.28 | -9.27 | 4.85 | |||||
Capital Expenditures, 5 Yr. CAGR % | 11.35 | 0.06 | -9.57 | -7.78 | -4.65 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | -16.12 | 55.41 | -1.57 | -4.63 | 7.95 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | -69.78 | 206.03 | 5.73 | -13.73 | 77.28 | |||||
Dividend Per Share, 5 Yr. CAGR % | 8.45 | 7.54 | 8.08 | 2.53 | 0 |
- Stock Market
- Stocks
- 1099 Stock
- Financials Sinopharm Group Co. Ltd.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















